Hybrid Tellurium–Lignin Nanoparticles with Enhanced Antibacterial Properties
Source abstract
Abstract
The surge of antibiotic-resistant bacteria is leading to the loss of effectiveness of antibiotic treatment, resulting in prolonged infections and even death. Against this healthcare threat, antimicrobial nanoparticles that hamper the evolution of resistance mechanisms are promising alternatives to antibiotics. Herein, we used Kraft lignin, a poorly valorized polymer derived from plant biomass, to develop novel hybrid tellurium-lignin nanoparticles (TeLigNPs) as alternative antimicrobial agents. The sonochemically synthesized TeLigNPs are comprised of a lignin matrix with embedded Te clusters, revealing the role of lignin as both a reducing agent and a structural component. The hybrid NPs showed strong bactericidal effects against the Gram-negative Escherichia coli and Pseudomonas aeruginosa, achieving more than 5 log bacteria reduction, while they only slightly inhibited the growth of the Gram-positive Staphylococcus aureus. Exposure of TeLigNPs to human cells did not cause morphological changes or reduction in cell viability. Studies on the antimicrobial mechanism of action demonstrated that the novel TeLigNPs were able to disturb bacterial model membranes and generate reactive oxygen species (ROS) in Gram-negative bacteria.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticles: synthesis and applications · Medical and Biological Ozone Research · Pigment Synthesis and Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Grup de Biotecnologia Molecular i Industrial, Department of Chemical Engineering, Universitat Politècnica de Catalunya, Rambla Sant Nebridi 22, Terrassa 08222, Spain
Funding
Ag?ncia de Gesti? d?Ajuts Universitaris i de Recerca · H2020 Food
References (61)
Show source-provided references
1. WHO. Antimicrobial Resistance: Global Report on Surveillance 2014; World Health Organization, 2014; pp 1–257.
2. CDC · 2019
3. ECDC/EMEA Joint Working Group · 2009
4. IACG · 2019
5. 10.1186/s12951-017-0308-z10.1186/s12951-017-0308-z ↗
6. 10.1021/acsami.9b2019310.1021/acsami.9b20193 ↗
7. 10.1002/adhm.20170150310.1002/adhm.201701503 ↗
8. 10.3390/ijms1709153410.3390/ijms17091534 ↗
9. 10.1038/s41598-019-54025-010.1038/s41598-019-54025-0 ↗
10. 10.1021/acsami.8b2186210.1021/acsami.8b21862 ↗
11. 10.1038/s41565-017-0013-y10.1038/s41565-017-0013-y ↗
12. 10.3390/ijms2011280810.3390/ijms20112808 ↗
13. 10.1371/journal.pone.000021110.1371/journal.pone.0000211 ↗
14. 10.1371/journal.pone.003545210.1371/journal.pone.0035452 ↗
15. 10.1039/c9mt00044e10.1039/c9mt00044e ↗
16. 10.1039/c9gc00131j10.1039/c9gc00131j ↗
17. 10.1007/s11051-018-4354-810.1007/s11051-018-4354-8 ↗
18. 10.1038/s41467-020-20445-010.1038/s41467-020-20445-0 ↗
19. Kus M. · 2018 · 39210.1016/B978-0-12-813351-4.00025-0 ↗
20. 10.2147/IJN.S17564010.2147/IJN.S175640 ↗
21. 10.1038/s41467-019-11898-z10.1038/s41467-019-11898-z ↗
22. 10.3389/fmicb.2015.0058410.3389/fmicb.2015.00584 ↗
23. 10.1002/bit.2514710.1002/bit.25147 ↗
24. 10.1088/1361-6528/ab4e3810.1088/1361-6528/ab4e38 ↗
25. 10.2147/IJN.S15795810.2147/IJN.S157958 ↗
26. 10.1038/nnano.2015.14110.1038/nnano.2015.141 ↗
27. 10.3390/antibiotics702004010.3390/antibiotics7020040 ↗
28. 10.1016/j.ijbiomac.2020.02.31110.1016/j.ijbiomac.2020.02.311 ↗
29. 10.3390/nano907099710.3390/nano9070997 ↗
30. 10.1016/j.actbio.2020.09.03810.1016/j.actbio.2020.09.038 ↗
31. 10.1099/mic.0.056903-010.1099/mic.0.056903-0 ↗
32. 10.1016/j.chemphyslip.2018.12.00310.1016/j.chemphyslip.2018.12.003 ↗
33. 10.1016/j.bbamem.2015.03.00310.1016/j.bbamem.2015.03.003 ↗
34. 10.1155/2017/895165810.1155/2017/8951658 ↗
35. Pankaj · 2011
36. 10.1021/acs.iecr.9b0636210.1021/acs.iecr.9b06362 ↗
37. 10.1002/app.4513610.1002/app.45136 ↗
38. 10.1016/j.ultsonch.2017.09.04910.1016/j.ultsonch.2017.09.049 ↗
39. 10.1016/j.ultsonch.2014.08.02110.1016/j.ultsonch.2014.08.021 ↗
40. 10.1021/bm500015j10.1021/bm500015j ↗
41. 10.1021/acssuschemeng.6b0090410.1021/acssuschemeng.6b00904 ↗
42. Shimazaki Y. · 2012
43. 10.1128/AEM.02207-1410.1128/AEM.02207-14 ↗
44. 10.1039/c8en01090k10.1039/c8en01090k ↗
45. 10.15376/biores.11.2.Espinoza_Acosta10.15376/biores.11.2.Espinoza_Acosta ↗
46. 10.3390/ijms1812270210.3390/ijms18122702 ↗
47. 10.1002/smll.20070059510.1002/smll.200700595 ↗
48. 10.1039/c2dt12266a10.1039/c2dt12266a ↗
49. 10.1016/j.colsurfb.2013.01.01010.1016/j.colsurfb.2013.01.010 ↗
50. 10.1016/j.ijbiomac.2015.09.066.10.1016/j.ijbiomac.2015.09.066. ↗
51. 10.1016/j.pmatsci.2017.12.00110.1016/j.pmatsci.2017.12.001 ↗
52. 10.1111/j.1574-6976.2009.00177.x10.1111/j.1574-6976.2009.00177.x ↗
53. 10.1007/s00203-006-0179-410.1007/s00203-006-0179-4 ↗
54. 10.1021/acsami.7b0021710.1021/acsami.7b00217 ↗
55. 10.1016/S0040-6090(99)00526-X10.1016/S0040-6090(99)00526-X ↗
56. 10.3389/fbioe.2020.0043910.3389/fbioe.2020.00439 ↗
57. 10.1039/c4sm02851a10.1039/c4sm02851a ↗
58. 10.1073/pnas.190464311610.1073/pnas.1904643116 ↗
59. 10.1016/j.bbamem.2006.04.00710.1016/j.bbamem.2006.04.007 ↗
60. 10.1074/jbc.M70884620010.1074/jbc.M708846200 ↗
61. 10.1021/acschembio.7b0023710.1021/acschembio.7b00237 ↗